
Sign up to save your podcasts
Or
Dr. Anna Wolska sits down with experts, Dr. Michelle Petri and Dr. Nick Ballew, analyzing the effectiveness of SLE treatments Belimumab and Anifrolumab. The conversation delves into their meticulous study, where they examined the 52-week SLE Responder Index (SRI)-4 responses, providing crucial data for informed lupus patient care. The study data, based on rigorous randomized trials and systematic literature reviews, offers clinicians invaluable insights into treatment decisions for people living with lupus.
Read the published article: http://dx.doi.org/10.1136/lupus-2023-000907
3.9
1414 ratings
Dr. Anna Wolska sits down with experts, Dr. Michelle Petri and Dr. Nick Ballew, analyzing the effectiveness of SLE treatments Belimumab and Anifrolumab. The conversation delves into their meticulous study, where they examined the 52-week SLE Responder Index (SRI)-4 responses, providing crucial data for informed lupus patient care. The study data, based on rigorous randomized trials and systematic literature reviews, offers clinicians invaluable insights into treatment decisions for people living with lupus.
Read the published article: http://dx.doi.org/10.1136/lupus-2023-000907
11,158 Listeners
41 Listeners
5 Listeners
49 Listeners
7 Listeners
5 Listeners
3 Listeners
3 Listeners
3 Listeners
10 Listeners
39 Listeners
14 Listeners
1 Listeners
47 Listeners
1 Listeners
6 Listeners
498 Listeners
281 Listeners
3,332 Listeners
3 Listeners
90 Listeners
24 Listeners
1,105 Listeners
1,672 Listeners
23 Listeners
350 Listeners
23 Listeners
32 Listeners
368 Listeners
43 Listeners
2 Listeners
0 Listeners
0 Listeners
2 Listeners